

## RESULTS

### Molecular karyotyping and validation of deletion

The entries of molecular karyotyping were 18 patients with KS (K1, K3, K5, K6, K7, K8, K9, K11, K12, K13, K16, K18, K20, K21, K22, K23, K34 and K38). We eliminated the data of patient K3 from copy number analysis, because it showed low quality data; that is, a single-nucleotide polymorphism (SNP) call rate of 82.51% and a quality control performance detection rate of 74.09%, probably because of DNA degradation during long-term storage. The other patients showed high call rates, enough for copy number analysis (SNP call rate of 90.07–97.72% and detection rate of 91.52–99.77%). We identified nine deleted regions, the lengths of which were between ~35 kb and ~1.27 Mb, and nine duplicated regions, of lengths between ~72 and ~495 kb, in the 17 patients analyzed (Table 1). As for the nine duplications detected, five of them were concordant to several observed gains in DGV, and four of them in each patient did not contain any known genes.

It is interesting that the deleted region of 9q21.11–q21.12 (~1.27 Mb in patient K16), which had not been registered in DGV, harbored four known genes: transient receptor potential cation channel, subfamily M, member 3 (*TRPM3*), Kruppel-like factor 9 (*KLF9*), structural maintenance of chromosomes protein 5 (*SMC5*) and MAM domain containing 2 (*MAMDC2*) (Figure 1d). The deletion of 3p26.2 (~205 kb in patient K9, Figure 1a) had involved a non-coding exon of the *SUMF1* gene. The deletion of 18p11.32 (~35 kb in patient K34, Figure 1b) containing the *CETN1* gene had one registration in DGV as Variation\_5044, which described only one observed loss and 14 observed gains in 95 individuals. The deletion of 4q13.2 (~1.26 Mb in patient K23, Figure 1c) and 20p12.1 (~152 kb in patient K6) did not carry any coding exon of any gene. The regions of 14q11.2 (~116 kb in patient K5) and 15q11.2 (~972 kb in patient K1 and K23) were non-pathological deletions with as many registrations as observed losses in DGV.


To validate the deletion of the detected region, we confirmed the loss of heterozygosities of the SNP probes present there using GTTYPE (data not shown) and carried out qPCR. The regions of *SUMF1* on 3p26.2 (for patient K9) and of *MAMDC2* on 9q21.11–q21.12 (for patient K16) had one copy in each patient compared with those in unaffected individuals (Figure 2). The deletion of *CETN1* on 18p11.32 (for patient K34) was inherited from his unaffected mother. As samples from the parents of patient K16 were unavailable, it was not possible to examine whether the deletion of 9q21 was *de novo*. But the deletion was not found in 95 normal Japanese individuals using qPCR (data not shown).

As a consequence of this copy number analysis, we considered the next four genes as candidate genes for KS: *TRPM3*, *KLF9*, *SMC5* and *MAMDC2*.

### Mutation screening and *in silico* analysis

Table 2 shows the results from mutation screening of the four candidate genes in 41 patients with KS. Ten base substitutions were found in the 41 patients, consisting of six registered SNPs, one unregistered SNP and three silent mutations. In addition, *SUMF1* (NM\_182760) and *CETN1* (NM\_004066) were also screened, but no mutations were detected (data not shown).

We checked the three silent mutations for splice site alteration using the GeneSplicer program, but no activation of the cryptic splice site was predicted. Although PANTHER classification of the four candidate genes did not show significant correlation for biological processes or pathway because of its small scale in number, some genes associated with developmental biology;



**Figure 2** Validation of deletion with quantitative PCR (qPCR). qPCR confirmed a loss of one copy in each patient: *SUMF1* at 3p26.2 for patient K9; *MAMDC2* at 9q21.1 for patient K16; *CETN1* at 18p11.32 for patient K34. The deletion of patient K34 was inherited from his unaffected mother. UA, unaffected individual. Error bars, s.d.

that is, DNA repair (*SMC5*) and mRNA transcription regulation (*KLF9*).

## DISCUSSION

We used high-resolution oligonucleotide array of GeneChip 250K NspI with a resolution of 30–100 kb and tried to find causative deletions or mutated genes for KS. Our molecular analysis did not strongly identify the causative gene for KS, but we identified a locus that possibly contributed to KS.

The deletion in patient K16, with a length of ~1.27 Mb at 9q21.11–q21.12, harbored four known genes: *TRPM3*, *KLF9*, *SMC5* and *MAMDC2* (Figure 1d). Unfortunately, her parents' DNAs were unavailable, but the region is unlikely to be a copy number variant (CNV) because it has not been known as CNV in DGV; moreover, the deletion was not found in 95 normal Japanese individuals using qPCR.

As mutation screening in the 41 patients with KS showed no pathogenic base substitution in these genes, we cannot state that

**Table 2** Mutation screening of candidate genes in 41 patients with Kabuki syndrome

Involving gene(s)	Base substitution	Amino acid change	Patient(s) with KS		dbSNP	Allele frequency among unaffected Japanese <sup>a</sup>	Results of mutation screening
			Homo	Hetero			
TRPM3	459C>T	A153A	0	1	NR	0	Synonymous
	4023G>A	S1341S	13	28	rs3739776	—	SNP, synonymous
KLF9	459C>T	V153V	0	1	NR	0	Synonymous
	SMC5	916G>A	V306I	37	4	rs1180116	—
		922T>C	C308R	21	10	rs1180117	—
MAMDC2	62T>C	L21P	0	2	NR	0.02	SNP, non-synonymous
	492C>T	T164T	0	1	NR	0	synonymous
	816C>T	Y272Y	11	16	rs2296772	—	SNP, synonymous
	867G>A	A289A	13	15	rs2296773	—	SNP, synonymous
	1063_1065 delAAA	K355 del	11	17	rs61609258	—	(SNP) synonymous; del/ins polymorphism

Abbreviations: *KLF9*, Kruppel-like factor 9; *MAMDC2*, MAM domain containing 2; *SMC5*, structural maintenance of chromosomes protein 5; SNP, single nucleotide polymorphism; *TRPM3*, transient receptor potential cation channel, subfamily M, member 3; dbSNP, registration number of database of SNP (<http://www.ncbi.nlm.nih.gov/SNP/>).  
<sup>a</sup>Allele frequency was calculated from 188 chromosomes of 94 individuals.

these genes are major genetic factors for KS. However, it is presumable that the genes have some etiological roles for KS because of its genetic heterogeneity. Ontology of the PANTHER classification suggested that the three genes were associated with developmental biology, such as mRNA transcription regulation. Moreover, the 1.27 Mb region of 9q21 was included in an earlier reported candidate locus of cleft lip/palate by meta-analysis of linkage analysis.<sup>24</sup> Patient K16 actually had velopharyngeal insufficiency because of a submucous cleft palate. Therefore, it is reasonable to consider that the deleted genes cooperated with the development of a cleft palate, which is often accompanied by KS.

Although the ~152 kb deletion within intron 5 of *C20orf133* (*MACROD2*) in patient K6 did not involve any coding exon and her parents' DNAs were unavailable, the deletion was neither registered as CNV in DGV nor was it found in 95 normal Japanese individuals by qPCR (data not shown). Maas *et al.*<sup>14</sup> reported *de novo* ~250 kb deletion, including exon 5 of *C20orf133* (*MACROD2*), in a patient with KS. Direct sequencing for the gene in 62 other patients with KS did not detect mutations,<sup>14,15</sup> but the gene may be one of the causative genes for KS in consideration of its genetic heterogeneity.

We focused this study on KS on deletion/duplication detected using oligonucleotide array and mutation screening of the coding genes within the region. One limitation of this study is its resolution. As a matter of course, a higher resolution array can detect smaller genomic rearrangements, which were undetectable in the same patient, as we showed here compared with an earlier study of BAC array CGH.<sup>18</sup> Although SNP probes are useful to examine loss of heterozygosity as a collateral evidence in deletions, unevenly distributed probes of the SNP array have a disadvantage for CNV detection. As various platforms on oligonucleotide array have developed, higher resolution platforms will have to be applied to search tiny genomic rearrangements in patients with KS. Another limitation is that we assumed that a single copy number change caused KS. It remains to be elucidated whether CNV association<sup>25</sup> contributes towards manifestations of KS. If further investigation with refined array technologies cannot find the etiology of KS, the direction of study for KS will have to be changed to find *de novo* sequence alteration or methylation aberration, including in the non-coding genomic regions.

In summary, we applied molecular karyotyping with GeneChip 250K array to detect copy number aberrations in 17 patients with KS

and screened four candidate genes in 41 patients with KS. We could not identify causative DNA alteration for KS, but the locus, 9q21.11-q21.12, including *TRPM3*, *KLF9*, *SMC5* and *MAMDC2*, may contribute to the cleft palate of KS. Further investigations will be needed as various array platforms have the potential to specify genomic alterations for KS.

#### ACKNOWLEDGEMENTS

We are grateful to the patients and their parents for their participation in this research. We also thank Ms Yasuko Noguchi, Ms Miho Ooga and Ms Chisa Hayashida for their technical assistance. NN was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Sports, Culture, Science and Technology of Japan, and was supported by SORST from Japan Science and Technology Agency (JST) (Nos. 17019055 and 19390095, respectively). KY was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Health, Labor and Welfare.

- Niikawa, N., Matsuura, N., Fukushima, Y., Ohsawa, T. & Kajii, T. Kabuki make-up syndrome: a syndrome of mental retardation, unusual faces, large and protruding ears, and postnatal growth deficiency. *J. Pediatr.* **99**, 565–569 (1981).
- Kuroki, Y., Suzuki, Y., Chyo, H., Hata, A. & Matsui, I. A new malformation syndrome of long palpebral fissures, large ears, depressed nasal tip, and skeletal anomalies associated with postnatal dwarfism and mental retardation. *J. Pediatr.* **99**, 570–573 (1981).
- Niikawa, N., Kuroki, Y., Kajii, T., Matsuura, N., Ishikiriyama, S., Tonoki, H. *et al.* Kabuki make-up (Niikawa-Kuroki) syndrome: a study of 62 patients. *Am. J. Med. Genet.* **31**, 565–589 (1988).
- White, S. M., Thompson, E. M., Kidd, A., Savarirayan, R., Turner, A., Amor, D. *et al.* Growth, behavior, and clinical findings in 27 patients with Kabuki (Niikawa-Kuroki) syndrome. *Am. J. Med. Genet.* **127A**, 118–127 (2004).
- Matsumoto, N. & Niikawa, N. Kabuki make-up syndrome: a review. *Am. J. Med. Genet.* **117C**, 57–65 (2003).
- Wessels, M. W., Brooks, A. S., Hoogeboom, J., Niermeijer, M. F. & Willers, P. J. Kabuki syndrome: a review study of three hundred patients. *Clin. Dysmorphol.* **11**, 95–102 (2002).
- Armstrong, L., Abd El Moneim, A., Aleck, K., Aughton, D. J., Baumann, C., Braddock, S. R. *et al.* Further delineation of Kabuki syndrome in 48 well-defined new individuals. *Am. J. Med. Genet.* **132A**, 265–272 (2005).
- Li, M., Zackai, E. H., Niikawa, N., Kaplan, P. & Driscoll, D. A. Kabuki syndrome is not caused by a microdeletion in the DiGeorge/velocardiofacial chromosomal region within 22q 11.2. *Am. J. Med. Genet.* **65**, 101–103 (1996).
- Makita, Y., Yamada, K., Miyamoto, A., Okuno, A. & Niikawa, N. Kabuki make-up syndrome is not caused by microdeletion close to the van der Woude syndrome critical region at 1q32-q41. *Am. J. Med. Genet.* **86**, 285–288 (1999).

- 10 Miyake, N., Harada, N., Shimokawa, O., Ohashi, H., Kurosawa, K., Matsumoto, T. *et al.* On the reported 8p22-p23.1 duplication in Kabuki make-up syndrome (KMS) and its absence in patients with typical KMS. *Am. J. Med. Genet.* **128A**, 170–172 (2004).
- 11 Hoffman, J. D., Zhang, Y., Greshock, J., Ciprero, K. L., Emanuel, B. S., Zackai, E. H. *et al.* Array based CGH and FISH fail to confirm duplication of 8p22-p23.1 in association with Kabuki syndrome. *J. Med. Genet.* **42**, 49–53 (2005).
- 12 Sanlaville, D., Genevieve, D., Bernardin, C., Amiel, J., Baumann, C., de Blois, M. C. *et al.* Failure to detect an 8p22–8p23.1 duplication in patients with Kabuki (Niikawa-Kuroki) syndrome. *Eur. J. Hum. Genet.* **13**, 690–693 (2005).
- 13 Kimberley, K. W., Morris, C. A. & Hobart, H. H. BAC-FISH refutes report of an 8p22–8p23.1 inversion or duplication in 8 patients with Kabuki syndrome. *BMC Med. Genet.* **7**, 46 (2006).
- 14 Maas, N. M., Van de Putte, T., Melotte, C., Francis, A., Schrander-Stumpel, C. T., Sanlaville, D. *et al.* The C20orf133 gene is disrupted in a patient with Kabuki syndrome. *J. Med. Genet.* **44**, 562–569 (2007).
- 15 Kuniba, H., Tsuda, M., Nakashima, M., Miura, S., Miyake, N., Kondoh, T. *et al.* Lack of C20orf133 and FLRT3 mutations in 43 patients with Kabuki syndrome in Japan. *J. Med. Genet.* **45**, 479–480 (2008).
- 16 Cuscó, I., del Campo, M., Vilardell, M., González, E., Gener, B., Galán, E. *et al.* Array-CGH in patients with Kabuki-like phenotype: identification of two patients with complex rearrangements including 2q37 deletions and no other recurrent aberration. *BMC Med. Genet.* **9**, 27 (2008).
- 17 Schoumans, J., Nordgren, A., Ruivenkamp, C., Brøndum-Nielsen, K., The, B. T., Annéren, G. *et al.* Genome-wide screening using array-CGH does not reveal microdeletions/microduplications in children with Kabuki syndrome. *Eur. J. Hum. Genet.* **13**, 260–263 (2005).
- 18 Miyake, N., Shimokawa, O., Harada, N., Sosonkina, N., Okubo, A., Kawara, H. *et al.* No detectable genomic aberrations by BAC Array CGH in Kabuki make-up syndrome patients. *Am. J. Med. Genet.* **140A**, 291–293 (2006).
- 19 Zhang, Z. F., Ruivenkamp, C., Staaf, J., Zhu, H., Barbaro, M., Petillo, D. *et al.* Detection of submicroscopic constitutional chromosome aberrations in clinical diagnostics: a validation of the practical performance of different array platforms. *Eur. J. Hum. Genet.* **16**, 786–792 (2008).
- 20 Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M. *et al.* Oncogenic mutations of ALK kinase in neuroblastoma. *Nature* **455**, 971–975 (2008).
- 21 Nannya, Y., Sanada, M., Nakazaki, K., Hosoya, N., Wang, L., Hangaishi, A. *et al.* A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. *Cancer Res.* **65**, 6071–6079 (2005).
- 22 Monis, P. T., Giglio, S. & Saint, C. P. Comparison of SYTO9 and SYBR Green I for real-time polymerase chain reaction and investigation of the effect of dye concentration on amplification and DNA melting curve analysis. *Anal. Biochem.* **340**, 24–34 (2005).
- 23 Thomas, P. D., Campbell, M. J., Kejariwal, A., Mi, H., Karlak, B., Daverman, R. *et al.* PANTHER: a library of protein families and subfamilies indexed by function. *Genome Res.* **13**, 2129–2141 (2003).
- 24 Marazita, M. L., Murray, J. C., Lidral, A. C., Arcos-Burgos, M., Cooper, M. E., Goldstein, T. *et al.* Meta-analysis of 13 genome scans reveals multiple cleft lip/palate genes with novel loci on 9q21 and 2q32–35. *Am. J. Hum. Genet.* **75**, 161–173 (2004).
- 25 Franke, L., de Kovel, C. G., Aulchenko, Y. S., Trynka, G., Zhernakova, A., Hunt, K. A. *et al.* Detection, imputation, and association analysis of small deletions and null alleles on oligonucleotide arrays. *Am. J. Hum. Genet.* **82**, 1316–1333 (2008).

Supplementary Information accompanies the paper on Journal of Human Genetics website (<http://www.nature.com/jhg>)

## Earwax, osmidrosis, and breast cancer: why does one SNP (538G>A) in the human ABC transporter *ABCC11* gene determine earwax type?

Yu Toyoda,\* Aki Sakurai,\*<sup>†</sup> Yasumasa Mitani,<sup>†,‡</sup> Masahiro Nakashima,<sup>§</sup> Koh-ichiro Yoshiura,<sup>||</sup> Hiroshi Nakagawa,\* Yasuo Sakai,<sup>||</sup> Ikuko Ota,<sup>†,#</sup> Alexander Lezhava,<sup>†</sup> Yoshihide Hayashizaki,<sup>†</sup> Norio Niikawa,<sup>||,\*\*</sup> and Toshihisa Ishikawa<sup>\*,†,1</sup>

\*Department of Biomolecular Engineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan; <sup>†</sup>Omics Science Center (OSC), RIKEN Yokohama Institute, Yokohama, Japan; <sup>‡</sup>K.K. DNAFORM, Yokohama, Japan; <sup>§</sup>Tissue and Histopathology Section, Atomic Bomb Disease Institute, and <sup>||</sup>Department of Human Genetics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; <sup>¶</sup>Department of Plastic and Reconstructive Surgery, Fujita Health University, Toyoake, Japan; <sup>#</sup>Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan; and <sup>\*\*</sup>Research Institute of Personalized Health Sciences, Health Sciences University of Hokkaido, Hokkaido, Japan

**ABSTRACT** One single-nucleotide polymorphism (SNP), 538G>A (Gly180Arg), in the *ABCC11* gene determines the type of earwax. The G/G and G/A genotypes correspond to the wet type of earwax, whereas A/A corresponds to the dry type. Wide ethnic differences exist in the frequencies of those alleles, reflecting global migratory waves of the ancestors of humankind. We herein provide the evidence that this genetic polymorphism has an effect on the *N*-linked glycosylation of *ABCC11*, intracellular sorting, and proteasomal degradation of the variant protein. Immunohistochemical studies with cerumen gland-containing tissue specimens revealed that the *ABCC11* WT protein was localized in intracellular granules and large vacuoles, as well as at the luminal membrane of secretory cells in the cerumen gland, whereas granular or vacuolar localization was not detected for the SNP (Arg180) variant. This SNP variant lacking *N*-linked glycosylation is recognized as a misfolded protein in the endoplasmic reticulum and readily undergoes ubiquitination and proteasomal degradation, which determines the dry type of earwax as a mendelian trait with a recessive phenotype. For rapid genetic diagnosis of axillary osmidrosis and potential risk of breast cancer, we developed specific primers for the SmartAmp method that enabled us to clinically genotype the *ABCC11* gene within 30 min.—Toyoda, Y., Sakurai, A., Mitani, Y., Nakashima, M., Yoshiura, K., Nakagawa, H., Sakai, Y., Ota, I., Lezhava, A., Hayashizaki, Y., Niikawa, N., Ishikawa, T. Earwax, osmidrosis, and breast cancer: why does one SNP (538G>A) in the human ABC transporter *ABCC11* gene determine earwax type? *FASEB J.* 23, 2001–2013 (2009)

**Key Words:** endoplasmic reticulum-associated degradation · genetic polymorphism · *N*-linked glycosylation · protein instability

CELL SECRETION IS AN IMPORTANT physiological process that ensures smooth metabolic activities and tissue repair

as well as growth and immunological functions in the body. Human earwax is a dimorphic trait consisting of wet or dry types. Wet earwax (cerumen) is a secretory product of ceruminous apocrine glands, whereas the dry type of earwax lacks oily components. In addition, apocrine glands can be found in the external auditory canal, breast, and axillary region; those physical characteristics also are concerned with apocrine glands. A positive association among the wet earwax type, axillary osmidrosis (1), colostrum secretion (2), and breast cancer risk (3, 4) has been suggested by phenotype-based analysis. Apocrine secretion occurs when the secretory process is accomplished with a partial loss of cell cytoplasm. The secretory materials may be contained within the secretory vesicles or dissolved in the cytoplasm, and during secretion they are released as cytoplasmic fragments into the glandular lumen or interstitial space (5).

Hitherto apocrine secretory mechanisms have not been well characterized (5). Although the biochemical and physiological pathways that regulate the apocrine secretory process are not clearly known, our recent finding that the nonsynonymous SNP 538G>A (rs17822931; Gly180Arg) in the *ABCC11* gene determines the type of earwax has shed light on the novel function of this ABC transporter in apocrine glands (6). In 2001, we and other groups independently cloned human *ABCC11* and *ABCC12* cDNAs (7–9). Both *ABCC11* and *ABCC12* genes are located on human chromosome 16q12.1 in a tail-to-head orientation with a separation distance of ~20 kb (7). Interestingly, there is an orthologous gene corresponding to

<sup>1</sup> Correspondence: Department of Biomolecular Engineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259-B-60 Nagatsuta, Midori-ku, Yokohama 226-8501, Japan. E-mail: tishikaw@bio.itech.ac.jp  
doi: 10.1096/fj.09-129098

the *ABCC12* gene in mammals (10, 11), but no gene orthologous to human *ABCC11* (11) has been found in mammals except for primates. Based on a database search, it is speculated that *ABCC11* is a paralogous gene generated by *ABCC12* gene duplication in the primate genome, including that of humans (12). Human *ABCC11* reportedly functions as an ATP-dependent efflux pump for amphipathic anions, including cyclic nucleotides, leukotriene C<sub>4</sub>, estrone 3-sulfate, dehydroepiandrosterone 3-sulfate (DHEAS), estradiol 17-β-D-glucuronide, and folic acid (13-16).

We have recently reported that one single-nucleotide polymorphism (SNP), 538G>A (Gly180Arg), in the *ABCC11* gene determines the type of earwax (6). This is the first example of a DNA polymorphism determining a visible genetic trait. The G/G and G/A genotypes correspond to the wet type of earwax, whereas A/A corresponds to the dry type. A functional assay has demonstrated that cells with allele A show a lower excretory activity for cGMP than those with allele G (6). Wide ethnic differences were also observed in the frequencies of those alleles (6). Furthermore, it has most recently been demonstrated that the genotype frequencies in the *ABCC11* and *EDAR* genes differ significantly between the Hondo and Ryukyu clusters in Japan (17).

At the present time, however, little is known about how genetic polymorphisms of the *ABCC11* gene affect the function of the ceruminous apocrine gland. The present study has two specific aims. First, to understand the molecular mechanism determining the earwax type, we investigated the effect of the SNP 538G>A (Gly180Arg) on the protein expression and intracellular localization of *ABCC11*. Second, to gain insight into the link between the genetic polymorphisms of *ABCC11* and the functions of apocrine glands, such as cerumen secretion and axillary osmidrosis, we designed a primer set for clinical genotyping.

In this article, we provide evidence that the SNP 538G>A (Gly180Arg) variant of human *ABCC11* lacking *N*-linked glycosylation is recognized as a misfolded protein in the endoplasmic reticulum (ER) and readily undergoes proteasomal degradation. This *ABCC11* protein degradation underlies the molecular mechanism to form the dry type of earwax as a mendelian trait with a recessive phenotype. Furthermore, we demonstrate that the wet type of earwax is genetically linked with axillary osmidrosis, which is recognized as a disease covered by the national health insurance system in Japan. Human *ABCC11* is suggested to play a pivotal role in the secretion of steroid metabolites from secretory cells in the apocrine glands.

## MATERIALS AND METHODS

### Collection of genomic DNA from volunteers and preparation of DNA samples

Under written informed consent, we collected blood samples from 124 Japanese volunteers at Nagasaki University (Na-

gasaki, Japan) during a period from January 2004 to December 2005. Genomic DNA was extracted from whole blood by the standard method. Protocols for the present study were approved by the Committee for the Ethical Issues on Human Genome and Gene Analysis, Nagasaki University. The clinical investigation was conducted according to the Declaration of Helsinki Principles. Briefly, all blood samples were collected in standard 2Na-EDTA-coated blood collection tubes. The samples were subjected to proteinase K digestion, and then genomic DNA was isolated by phenol/chloroform extraction and subsequently by ethanol precipitation. Part of the *ABCC11* gene including the 538G>A alleles was amplified by PCR with the following primers: EWX1, 5'-TGCAAAGAGAT-TCCACCAGTT-3'; and EWX2, 5'-AAGGTCTTCATTTTCTA-GACAGC-3'.

### Diagnosis of axillary osmidrosis in Japanese patients and genotyping

All procedures for the diagnosis of axillary osmidrosis patients and their genotyping were performed according to the protocol approved by the Ethical Review Board of Fujita Health University School of Medicine (Nagoya, Japan). The clinical investigation was conducted according to the Declaration of Helsinki Principles. Fourteen axillary osmidrosis patients participated in this study under written informed consent. All of the patients expressed their subjective views on symptoms by answering survey inquiries. Axillary osmidrosis was diagnosed basically from both the self-declaration of patients and the odor-smelling test carried out by authorized medical doctors. Earwax type was determined from wax samples obtained by stirring a cotton swab in the external auditory canal of the patient. Individual genomic DNA was obtained from 2 ml of whole blood by using QuickGene-610L (Fujifilm Co., Tokyo, Japan) according to the manufacturer's protocol. To sequence the SNP 538G>A, the following PCR primers were designed: P1, 5'-TGTCACATGCAAAGAGAT-TCC-3'; and P2, 5'-CTCCTGGCATGGACTTGAACA-3'. To identify the Δ27 mutation, we designed one set of primers: P3, 5'-AGGTCTCTAGGGCCTGAAGTA-3'; and P4, 5'-AGCCT-TCACCTTCCCATTGCC-3'. The experiments to determine the genotype of each patient with *ABCC11* gene amplification by PCR and DNA sequencing were carried out in a masked manner.

### DNA sequence analysis

DNA sequence analysis was carried out by using BigDye Terminator 3.1 (Applied Biosystems Inc., Foster City, CA, USA) after ExoSAP-IT treatment, and with an Autosequencer Model 3100 (Applied Biosystems Inc.), according to the manufacturer's protocol. The sequences were aligned with an AutoAssembler (Applied Biosystems Inc.) and visualized with Sequencher 4.7 Demo (Hitachi Software Engineering Co., Ltd., Tokyo, Japan) to find SNPs or mutations.

### Data analysis

SNP data on the polymorphisms of *ABCC11* were obtained from the dbSNP database of the National Center for Biotechnology Information (NCBI; Bethesda, MD, USA). The hydropathy profile of the *ABCC11* protein deduced from the cDNA sequence was calculated with the Kyte-Doolittle hydropathy algorithm (18). Potential *N*-linked glycosylation sites were predicted with Genetyx-Win 5.1. (Software Development Co., Ltd., Tokyo, Japan)

## Polyclonal antibody against ABCC11

The cytoplasmic domain (aa 746–804) close to the first ATP-binding cassette, located between transmembrane domains 6 and 7 (TM6 and TM7) of the ABCC11 protein, was selected as an epitope for development of the polyclonal antibody. The epitope-encoding cDNA (2236–2412) was inserted into the pGEX-2T vector (GE Healthcare, Little Chalfont, UK), and then *Escherichia coli* strain BL21 [F<sup>-</sup>, *ompT*, *hsdS*(r<sub>B</sub><sup>-</sup>, m<sub>B</sub><sup>-</sup>), *gal*] cells were transformed with the vector to produce a glutathione-S-transferase (GST)-like fusion peptide. The expressed fusion peptide was isolated by using a glutathione-affinity gel column (Pierce, Rockford, IL, USA) according to the manufacturer's protocol. The epitope peptide was then recovered by PreScission Protease digestion (GE Healthcare). The anti-ABCC11 polyclonal antibody was produced by immunization of rabbits with the epitope peptide. The antiserum was purified through an affinity column and used for immunohistochemistry and immunoblotting studies.

## Immunohistochemical detection of ABCC11 expressed in the ceruminous apocrine gland

External auditory canal tissues were obtained, with informed consent, from a patient undergoing surgical excision of a squamous cell carcinoma around the ear at Nagasaki University. The tissue samples were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS, pH 7.4) at 4°C overnight, embedded in paraffin, and sectioned at 4 µm in thickness. After antigen retrieval by microwave treatment in 0.01 M citrate buffer (pH 6.0), deparaffinized sections were preincubated with 10% normal goat serum. Thereafter, tissues were reacted with anti-ABCC11 rabbit polyclonal antibody at 1:500 dilution. The slides were subsequently incubated with Alexa Fluor 488-conjugated goat anti-rabbit IgG antibody (Invitrogen Co., Carlsbad, CA, USA). Specimens were counterstained with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI; Vysis Inc., Downers Grove, IL, USA), visualized, and photographed with a fluorescence microscope (Zeiss Axioplan2; Carl Zeiss Japan, Tokyo, Japan) equipped with a charge-coupled device camera (19).

## Expression of ABCC11 in Sf9 insect cells

The cDNA of human ABCC11 WT was inserted into the pFastBac1 vector (Invitrogen) between the restriction enzyme sites of *Xba*I and *Hind*III. To express ABCC11 in insect cells, recombinant baculoviruses were generated with the Bac-to-Bac baculovirus expression systems (Invitrogen) according to the manufacturer's protocols. Insect *Spodoptera frugiperda* Sf9 cells (1.0 × 10<sup>6</sup> cells/ml) were infected with the recombinant baculovirus and cultured in NIM-Ex Insect serum-free medium (Nosan Co., Yokohama, Japan) supplemented with penicillin (100 U/ml), and streptomycin (100 µg/ml) (Invitrogen) with gentle shaking at 28°C. Three days after infection, cells were harvested by centrifugation. To prepare the whole-cell lysate, cells were subsequently washed with PBS and collected by centrifugation.

## Generation of ABCC11 variant forms

The human ABCC11 WT or G180R cDNA was inserted into the pcDNA3.1/Hygro(-) vector (Invitrogen) between the restriction enzyme sites of *Xho*I/*Sal*I and *Hind*III, respectively. The resulting expression construct [ABCC11 WT-pcDNA3.1/Hygro(-)] was used as the template for site-directed mutagenesis to obtain ABCC11 variants, *i.e.*, N838Q, N844Q, and N838Q/N844Q. To generate Asn-to-Gln variant forms of

ABCC11, a codon (AAT) encoding asparagine was converted to CAA by using *Pfu Turbo* DNA polymerase and the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's protocol. The sequences of internal complementary PCR primers used for the site-directed mutagenesis, as well as the corresponding PCR conditions, are summarized in Supplemental Table 1. To generate the N838Q/N844Q variant, ABCC11 N838Q-pcDNA3.1/Hygro(-) was used as the template. Each variant cDNA generated in the pcDNA3.1/Hygro(-) plasmid was subjected to nucleotide sequence analysis (Shimadzu Co., Kyoto, Japan). To substitute Gly180 to Arg, Lys, His, Asp, Glu, AL, or Pro in the ABCC11 WT protein, the codon (GGG) encoding the Gly residue in TM1 was changed by site-directed mutagenesis, as described above. The PCR primers used for the site-directed mutagenesis are shown in Supplemental Table 2. Furthermore, hitherto known nonsynonymous SNP variants of ABCC11 were generated in the same manner as described above (see Supplemental Table 3 for the PCR primers used for site-directed mutagenesis).

## Expression of ABCC11 WT and variants in Flp-In-293 cells

Flp-In-293 cells (Invitrogen) were maintained in high-glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, penicillin (100 U/ml), and streptomycin (100 µg/ml) in a humidified atmosphere at 37°C with 5% CO<sub>2</sub> in air, as described previously (20–22). Flp-In-293 cells were replated onto 35-mm dishes at a concentration of 1.0 × 10<sup>6</sup> cells/dish. After 24 h, the cells were transfected with the ABCC11-pcDNA3.1/Hygro(-) vector by using Lipofectamine 2000 (Invitrogen). The amount of plasmid DNA used for transfection was adjusted to be the same among ABCC11 WT and its variants. To inhibit proteasomal degradation when needed, cells at 24 h after transfection were cultivated in the presence of 2 µM MG132 for a further 24 h.

At 48 h after the transfection, cells were washed with PBS and then treated with lysis buffer A containing 50 mM Tris/HCl (pH 7.4), 1% (w/v) Triton X-100, 1 mM dithiothreitol, and protease inhibitor mixture (CompleteTM Mini; Nacalai Tesque, Inc., Kyoto, Japan). The cell suspension sample was homogenized by passage through a 27-gauge needle and then centrifuged at 800 *g* at 4°C for 10 min. The resulting supernatant fraction (whole-cell lysate) was transferred to a new tube, and the protein concentration was quantified by using the BCA Protein Assay Kit (Pierce, Rockford, IL, USA).

## Detection of ABCC11 mRNA by reverse transcription-PCR

Total RNA was extracted from the ABCC11-transfected cells with the High-Pure RNA Isolation Kit (Roche Ltd., Mannheim, Germany) according to the manufacturer's protocol. cDNA was prepared from the extracted RNA in a reverse transcriptase reaction by using the High Capacity cDNA Archive kit (Applied Biosystems Inc.) and random hexamers, according to the manufacturer's instructions. The mRNA levels of ABCC11 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were determined by PCR in an iCycler<sup>TM</sup> thermal cycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA) with the following specific primers: ABCC11, 5'-AGCT-TACGGAGTCGCTTAGATGA-3' and 5'-TGGCTGTGCGTT-GGTTGA-3'; and GAPDH, 5'-AATTCATGGCACCGTCA-A-3' and 5'-CATGAGTCCTTCCACGATACCA-3'. The PCR reaction consisted of a hot-start incubation at 95°C for 2 min, followed by 95°C for 30 s, 56°C for 30 s, and 72°C for 30 s for 25 cycles. The PCR products were then analyzed by 2.0%

(w/v) agarose gel electrophoresis and detected under UV light by using ethidium bromide.

#### Analysis of N-linked glycosylation of ABCC11

The whole-cell lysates (150  $\mu$ g of protein) were incubated with 190 U of either peptide N-glycosidase F (PNGase F; New England Biolabs, Ipswich, MA, USA) or endoglycosidase H (Endo H; New England Biolabs) at 37°C for 10 min before immunoblot analysis.

#### Immunoblotting detection of ABCC11 expressed in Flp-In-293 cells

The ABCC11 protein expressed in Flp-In-293 cells was detected by immunoblotting with the anti-ABCC11 polyclonal antibody. Briefly, samples were separated by SDS-PAGE (7.5% polyacrylamide slab gel) and transferred to Hy-bond ECL nitrocellulose membrane (GE Healthcare) by electroblotting at 15 V for 70 min. One hour after blocking in Tris-buffered saline containing 0.05% (v/v) Tween 20 (TTBS) and 5% (w/v) skim milk, immunoblotting was performed by using anti-human ABCC11 antibody (1:1000 dilution) as the first antibody and a goat anti-rabbit IgG-horseradish peroxidase (HRP)-conjugate (1:2000; Zymed, San Francisco, CA, USA) as the second antibody. HRP-dependent luminescence was developed by using Western Lightning Chemiluminescence Reagent Plus (PerkinElmer Life Sciences, Boston, MA, USA) and detected with a Lumino Imaging Analyzer FAS-1000 (Toyobo, Osaka, Japan). To detect GAPDH, used as an internal loading control, immunoblot detection was carried out in the same manner as described above, except for the use of mouse monoclonal anti-GAPDH antibody (1:2000; American Research Products, Belmont, MA, USA) as the primary antibody and HRP-conjugated horse anti-mouse IgG (1:3000; Cell Signaling Technology, Inc., Beverly, MA, USA) as the second antibody.

#### Immunofluorescence microscopy

Flp-In-293 cells were replated onto 35-mm dishes at a concentration of  $1.0 \times 10^6$  cells/dish. After 24 h, the cells were transfected with the ABCC11-pcDNA3.1/Hyg(-) vector by using Lipofectamine 2000 (Invitrogen), as described above. At 36 h after transfection, ABCC11-expressing Flp-In-293 cells were seeded onto collagen type I-coated coverslips and incubated under the above-mentioned culture conditions for a further 36 h. Cells were fixed with 4% paraformaldehyde in PBS at room temperature for 20 min. Thereafter, cell membranes were permeabilized by incubation with 0.02% Triton X-100 in PBS at room temperature for 5 min. To block the free aldehyde groups of formaldehyde, cells were treated with 10 mg/ml glycine in PBS at room temperature for 10 min, followed by a further incubation with 0.5% (w/v) bovine serum albumin (BSA) in PBS at room temperature for 1 h. To detect the ABCC11 protein, cells were treated with the anti-ABCC11 antibody (1:500 dilution) as the primary antibody and subsequently with the Alexa Fluor 488-conjugated goat anti-rabbit IgG antibody (1:1000; Invitrogen). In the same preparations, nuclear DNA was stained with 4  $\mu$ g/ml propidium iodide in PBS containing 0.5% (w/v) BSA. The immunofluorescence of Flp-In-293 cells was detected with a laser-scanning confocal fluorescence microscope (IX70/Fluoview; Olympus, Tokyo, Japan).

#### Detection of SNP 538G>A in ABCC11 gene by SmartAmp method

Templates used for the SmartAmp (K.K. DNAFORM, Yokohama, Japan) detection of the SNP 538G>A in the *ABCC11*

gene were prepared from genomic DNA samples that were incubated at 98°C for 3 min. After chilling on ice, the sample preparation (20 ng of genomic DNA) was added directly into the reaction mixture (total volume of 25  $\mu$ l) containing 2.0  $\mu$ M folding primer (FP), 2.0  $\mu$ M turn-back primer (TP), 1.0  $\mu$ M boost primer (BP), 0.25  $\mu$ M of each outer primer (OP1 and OP2), 20  $\mu$ M competitive probe (CP), 1.4 mM dNTPs, 5% DMSO, 20 mM Tris-HCl (pH 8.0), 10 mM KCl, 10 mM  $(\text{NH}_4)_2\text{SO}_4$ , 8 mM  $\text{MgSO}_4$ , 0.1% (v/v) Tween<sup>®</sup>20, 1:100,000 SYBR<sup>®</sup> Green I (Takara Bio Inc., Shiga, Japan), and 0.24 U/ $\mu$ l *Aac* DNA polymerase (K.K. DNAFORM). SmartAmp reaction mixtures were incubated at 60°C for 60 min under an isothermal condition in a real-time PCR system (Mx3000P; Stratagene), where changes in the fluorescence intensity of SYBR Green I dye indicating DNA amplification were monitored during the reaction.

#### Statistical tests

Experimental data were analyzed by determining the statistical significance according to Student's *t* test.


## RESULTS

#### Localization of ABCC11 in secretory cells of human ceruminous apocrine glands

Fig. 1A displays photomicrographs of wet- and dry-type ceruminous apocrine glands stained with hematoxylin-eosin. In this study, we obtained the samples from Japanese subjects carrying the heterozygous (538G/A) and SNP homozygous (538A/A) alleles. Wet-type ceruminous apocrine glands in the subjects carrying heterozygous (538G/A) alleles are well developed, and they exhibited large luminal cavities as compared with dry-type ceruminous apocrine glands (homozygous 538A/A). Such morphological differences were consistent with previously reported observations for wet and dry types of human ceruminous glands (23).

To elucidate the expression and cellular localization of the ABCC11 protein in the ceruminous apocrine gland, we developed an ABCC11-specific polyclonal antibody raised against the epitope encoding amino acid residues 746–804 in the ABCC11 protein. The specificity and immunological activity of this antibody were confirmed as described below. Immunofluorescence staining of human tissue specimens containing cerumen glands revealed the expression of ABCC11 in the luminal domain of the plasma membrane of secretory cells in both wet- and dry-type ceruminous glands (Fig. 1B). It is noteworthy, however, that ABCC11 was predominantly localized in intracellular granules and large vacuoles in the secretory cells of wet-type ceruminous glands (Fig. 1B). In contrast, such granular and vacuolar localization of ABCC11 was not detected in the dry-type ceruminous glands (Fig. 1B). It is likely that the nonsynonymous SNP 538G>A (Gly180Arg) greatly affects the cellular localization of the ABCC11 protein in secretory cells.






**Figure 1.** Microscopic pictures of wet- and dry-type ceruminous apocrine glands after hematoxylin-eosin staining and immunofluorescence staining of human ABCC11 protein. **A)** External auditory canal tissues were fixed with 4% paraformaldehyde in PBS (pH 7.4) overnight at 4°C, embedded in paraffin, and sectioned at 4 μm in thickness. Tissue sections were then stained with hematoxylin and eosin. **B)** Immunofluorescence staining of human ABCC11 protein in tissue specimens containing ceruminous apocrine glands, from human subjects carrying heterozygous (538G/A) and SNP homozygous (538A/A) alleles. ABCC11 protein expressed in secretory cells of wet- and dry-type ceruminous apocrine glands, 538G/A and 538A/A, was immunologically detected with ABCC11-specific polyclonal antibody and Alexa Fluor 488 (green). Cellular nuclei were stained with Hoechst 33342 (blue). Scale bars = 100 μm (A); 40 μm (B).

#### Validation of the ABCC11-specific antibody

**Fig. 2** provides evidence that the polyclonal antibody is specific to human ABCC11. We expressed ABCC11 WT in Sf9 insect cells and Flp-In-293 human embryonic kidney cells by using pFastBac1 and pcDNA3.1/Hygro(-) vectors, respectively. Immunoblotting performed with the polyclonal antibody revealed one immunologically posi-

tive band (**Fig. 2C**, left column, arrowhead) in the ABCC11-expressing Sf9 cells. The molecular weight of the protein band was estimated to be ~150,000 (**Fig. 2C**). On the contrary, in the case of Flp-In-293 cells, two immunologically positive bands were observed at molecular weights of 180,000 and 150,000 (**Fig. 2C**, right column). After the sample was treated with PNGase F, the larger band (MW=180,000) disappeared, and one single im-



**Figure 2.** Expression and detection of ABCC11 expressed in Sf9 and Flp-In-293 cells by immunoblotting. **A)** cDNA of human ABCC11 WT was inserted into the pFastBac1 vector between restriction enzyme sites of *Xba*I and *Hind*III. To express ABCC11 in insect cells, recombinant baculoviruses were generated with the Bac-to-Bac baculovirus expression system. Insect Sf9 cells were then infected with recombinant baculoviruses. **B)** Human ABCC11 WT or G180R cDNA was inserted into pcDNA3.1/Hygro(-) vector between restriction enzyme sites of *Xho*I/*Sa*I and *Hind*III, respectively. Resulting expression construct [ABCC11 WT-pcDNA3.1/Hygro(-)] was used as template for site-directed mutagenesis with corresponding primers (Supplemental Tables 1 to 3). Human Flp-In-293 cells were transfected with expression vector by using Lipofectamine 2000 to express ABCC11 in cells. **C)** ABCC11 protein expressed in Sf9 and Flp-In-293 cells was detected by immunoblotting with anti-ABCC11 polyclonal antibody. ABCC11 protein expressed in Sf9 cells was not glycosylated, whereas it was N-linked glycosylated in Flp-In-293 cells. The N-linked glycosylated form of ABCC11 (MW=180,000) was changed to the nonglycosylated form (MW=150,000) by PNGase F treatment.



munologically positive band remained to be detected at the molecular weight of 150,000 (Fig. 2C). This molecular weight is consistent with that estimated from the ABCC11 cDNA. Thus, these observations strongly suggest that the ABCC11 WT protein is *N*-glycosylated in mammalian cells.


#### Expression of ABCC11 WT and SNP variant in Flp-In-293 cells

To understand the molecular mechanism underlying the difference in cellular localization of the ABCC11 WT and the SNP variant (Fig. 1B), we expressed both types (WT and R180) in Flp-In-293 cells *in vitro*. Figure 3 shows the differential interference and immunofluorescence images of Flp-In-293 cells expressing ABCC11 WT and R180 variant proteins, as well as Flp-In-293 cells transfected with a mock vector. These ABCC11 proteins were probed with the polyclonal antibody and then labeled with green fluorescence dye (Alexa Fluor 488), whereas DNA in the nuclei was stained with propidium iodide (red fluorescence). Strong green fluorescence was observed at the plasma membrane and within intracellular compartments in Flp-In-293 cells expressing ABCC11 WT. In the case of the SNP variant, however, expression of the ABCC11 R180 variant at the plasma membrane was negligibly low. In contrast, the


variant protein was detected within intracellular compartments proximal to the cellular nuclei in Flp-In-293 cells.

#### Protein expression levels of ABCC11 WT and SNP variant and their *N*-linked glycosylation status

In accordance with the results shown in Fig. 3, immunoblotting experiments revealed a significant difference in the protein expression level between the WT (G180) and the SNP variant (R180) of ABCC11 (Fig. 4A). Despite having similar mRNA levels, the expression level of the R180 variant protein was much lower than that of the WT (Fig. 4A). Interestingly, the R180 protein level was remarkably (14-fold) enhanced by treatment of the cells with the proteasome inhibitor MG132 (Fig. 4B). In contrast, the protein level of the WT was only moderately affected by MG132 treatment (Fig. 4B), suggesting that the R180 protein is more susceptible to proteasomal degradation than the WT. Furthermore, the R180 protein was not the *N*-linked glycosylated form, whereas the WT was expressed as both *N*-linked glycosylated and nonglycosylated forms (Fig. 4C). The *N*-linked glycan was digested by PNGase F, but not by Endo H (Fig. 4D).



**Figure 3.** Immunocytochemical staining of Flp-In-293 cells expressing ABCC11 WT and R180 variant proteins. Differential interference (A, C, E) and immunofluorescence images (B, D, F). ABCC11 proteins were immunologically detected with ABCC11-specific polyclonal antibody and Alexa Fluor 488 (green). Cellular nuclei were stained by propidium iodide (red). Antibody interacts with epitope peptide residing in cytoplasmic domain (aa 746–804) between TM6 and TM7. Since Gly180 or Arg180 residue resides in TMI, this amino acid alteration (Gly180Arg) does not affect immunoreactivity. Scale bars = 10  $\mu$ m.



**Figure 4.** Effect of SNP 538G>A (Gly180Arg) on expression of human ABCC11 protein in Flp-In-293 cells. **A)** Levels of ABCC11 WT and R180 variant proteins in Flp-In-293 cells. Prior to SDS-PAGE separation, cell lysate samples were treated with PNGase F. Data are expressed as means  $\pm$  SD;  $n = 3$ . \* $P < 0.05$  vs. WT. Mock:  $P = 0.013$ ; R180:  $P = 0.016$ . **B)** Effect of MG132 on expression levels of ABCC11 WT and R180 variant proteins. ABCC11 and GAPDH (loading marker) were detected by immunoblotting. MG132-induced increases in protein levels of ABCC11 WT and R180 variant are normalized and expressed as means  $\pm$  SD;  $n = 3$ . **C, D)** *N*-linked glycosylation status of ABCC11 WT and R180 variant proteins. WT and R180 variant of ABCC11 were separately expressed in Flp-In-293 cells, and mRNA and protein levels of ABCC11 were detected. Prior to SDS-PAGE separation,

cell lysate samples were treated with PNGase F or Endo H. *N*-linked glycosylated (G) and nonglycosylated (non-G) ABCC11 proteins were detected by immunoblotting. GAPDH, a control for equal loading, was detected in a similar manner.

#### Identification of *N*-linked glycosylation sites in ABCC11 WT protein

Based on the amino acid sequence of ABCC11, a total of 8 potential *N*-linked glycosylation sites (Asn-X-Thr/Ser) was predicted (Fig. 5A). The ABCC11 protein has 12 transmembrane helices, and its hydropathy profile indicates that only Asn838 and Asn844 reside in an extracellular loop between transmembrane helices TM7 and TM8 (Fig. 5A). Thus, we changed these Asn residues to Gln by site-directed mutagenesis and then expressed the protein in Flp-In-293 cells. Substitution of both Asn838 and Asn844 to Gln residues completely diminished *N*-linked glycosylation of the ABCC11 WT (Fig. 5B), demonstrating that these two Asn residues are *N*-linked glycosylation sites in the ABCC11 WT protein.

We hypothesized that amino acid substitution at 180 in the first transmembrane helix (TM1) might affect *N*-linked glycosylation of ABCC11. To examine our hypothesis, we substituted Gly180 to Arg, Lys, His, Asp, Glu, AL, and Pro in the ABCC11 WT protein. The substitution of Gly180 to a positively or negatively charged amino acid (*i.e.*, Arg, Lys, His, Asp, or Glu) diminished *N*-linked glycosylation of ABCC11, whereas substitution to a neutral amino acid (*i.e.*, AL or Pro) had no great effect (Fig. 5C). It is suggested that the electrostatic charge (either positive or negative) at aa




180 in the TM1 interferes with correct folding of the *de novo* synthesized ABCC11 protein in the ER.

#### Effect of nonsynonymous SNPs and a $\Delta 27$ mutation on the *N*-linked glycosylation of ABCC11

Furthermore, we created previously known nonsynonymous SNP variants and the  $\Delta 27$  mutant of ABCC11 (Fig. 6A) and expressed them in Flp-In-293 cells to examine their *N*-linked glycosylation status. The rare deletion mutation  $\Delta 27$  results from the removal of a 9-aa stretch (Asp1313–Arg1321) from the C-terminal intracellular region of the ABCC11 protein (6). Both the rare mutation and G180R provide the dry type of earwax (6). Among the variants tested, only G180R and  $\Delta 27$  diminished *N*-linked glycosylation of ABCC11 (Fig. 6B). Like the SNP variant R180 (Fig. 4A, B), the expression level of the  $\Delta 27$  mutant protein was low (Fig. 6C), whereas it was significantly enhanced by MG132 treatments (Fig. 6D). Thus, lack of *N*-linked glycans of ABCC11 appears to be related with the dry type of human earwax.

#### Clinical genotyping of the SNP 538G>A (Gly180Arg) in the ABCC11 gene by the SmartAmp method

We tried to create a clinical method to genotype the SNP 538G>A in the human *ABCC11* gene. For rapid genotyping, we have recently developed the SmartAmp method







**Figure 5.** Identification of *N*-linked glycosylation sites in ABCC11 protein and effect of amino acid substitutions at 180 on *N*-linked glycosylation of ABCC11. *A*) Hydropathy plot of human ABCC11 protein indicating putative *N*-linked glycosylation sites, transmembrane domains, and ATP-binding cassette (ABC). Arrows indicate Asn residues; *N*-linked glycosylated Asn838 and Asn844 are shown in boxes. *B*) Effect of substitution of Asn838 and Asn844 to Gln on *N*-linked glycosylation status of ABCC11. Asn838 and Asn844 were substituted to Gln by site-directed mutagenesis with PCR primers listed in Supplemental Table 1. *N*-linked glycosylated (G) and nonglycosylated (non-G) forms of ABCC11 protein were detected by immunoblotting.


*C*) Effect of electrostatic charges at amino acid residue 180 on *N*-linked glycosylation status of ABCC11. Gly180 residue in ABCC11 WT protein was substituted to Arg, Lys, His, Asp, Glu, AL, and Pro by site-directed mutagenesis with PCR primers listed in Supplemental Table 2. ABCC11 protein was detected by immunoblotting; glycosylation forms are indicated. Asterisk (\*) indicates no *N*-linked glycosylation of ABCC11.

that enables us to detect genetic polymorphisms or mutations in ~30 min under isothermal conditions (24). **Figure 7A** schematically illustrates the strategy of SNP detection by the SmartAmp method. To determine the

SNP 538G>A (Gly180Arg) in the *ABCC11* gene, we prepared one set of primers designated TP, FP, BP, OP, and CP (Fig. 7B). The TPs discriminate the polymorphism 538G or 538A in the *ABCC11* gene, and the CPs



**Figure 6.** Effect of nonsynonymous SNPs and a  $\Delta 27$  mutation on the *N*-linked glycosylation status of ABCC11. *A*) Locations of hitherto reported nonsynonymous SNPs and  $\Delta 27$  are indicated in putative structure of ABCC11. *B*) Variants of nonsynonymous SNPs and  $\Delta 27$  were created by site-directed mutagenesis with PCR primers listed in Supplemental Table 3. Those variant forms were expressed in Flp-In-293 cells. *N*-linked glycosylated (G) and nonglycosylated (non-G) forms of ABCC11 protein were detected by immunoblotting. Asterisk (\*) indicates no *N*-linked glycosylation of ABCC11. *C*) Levels of ABCC11 WT and  $\Delta 27$  mutant proteins in Flp-In-293 cells. Samples were processed in the same manner as described in Fig. 4A. *D*) Effect of MG132 on expression levels of ABCC11 WT and  $\Delta 27$  mutant proteins. ABCC11 and GAPDH (loading marker) were detected by immunoblotting. Data are expressed as means  $\pm$  SD;  $n = 3$ .



**Figure 7.** Strategy for SmartAmp-based detection of SNP 538G>A in *ABCC11* gene. **A)** Schematic illustration of SmartAmp-based SNP detection. SNP 538G>A resides in exon 4 of *ABCC11* gene on chromosome 16q12. **B)** Partial genomic DNA sequences of *ABCC11* gene carrying WT (538G) and SNP (538A) alleles and sequences of primers used for SmartAmp assay.

inhibit the background amplification from mismatch sequence pairs (25, 26) (Fig. 7A). These primers selectively recognized the SNP 538G>A of the *ABCC11* gene to discriminate homozygous 538G/G (wet type), heterozygous 538G/A (wet type), and homozygous 538A/A (dry type) in genomic DNA (Fig. 8A). By this new method, we typed the SNP in genomic DNA samples from a total of 124 healthy volunteers and compared the results obtained by DNA sequencing. Neither false positives nor false negatives were observed (Fig. 8B). Thus, the perfect matching validated the SmartAmp-based SNP typing method for use in clinical practice.

Since previous phenotype-based studies have suggested a positive association between the wet-type earwax and axillary osmidrosis (1), we analyzed the SNP in the *ABCC11* gene of Japanese axillary osmidrosis patients. In this clinical study, axillary osmidrosis was diagnosed basically from both the self-declaration of patients and the odor-smelling test carried out by authorized medical doctors. The earwax type was determined from wax samples obtained by stirring a cotton swab in the external auditory canal of the patient. **Table 1** summarizes the clinical results from this study with respect to the *ABCC11* genotype as well as axillary osmidrosis and earwax types. It is notable that all axillary osmidrosis patients carrying the 538 allele as either WT homozygous (538G/G) or heterozygous (538G/A) have the wet type of earwax, without exception. Although the population size was rather small in this study, the *ABCC11* WT allele is suggested to be a genetic biomarker for clinical diagnosis of axillary osmidrosis.

## DISCUSSION


### Proteasomal degradation of *ABCC11* R180 is the molecular mechanism determining the dry-type earwax

The present study provides direct evidence that human *ABCC11* WT is an *N*-linked glycosylated protein, which

is localized in intracellular granules and large vacuoles as well as at the luminal membrane of secretory cells in the cerumen apocrine gland. *N*-linked glycosylation occurs at both Asn838 and Asn844 in the extracellular loop between TM7 and 8 TM8 of the *ABCC11* WT protein. In contrast, the SNP variant R180 lacks *N*-linked glycosylation and readily undergoes proteasomal degradation, most probably *via* ubiquitination. As a consequence, granular or vacuolar localization was not detected in the cerumen apocrine gland for the SNP variant.

Morphological differences were previously reported between the secretory cells of wet and dry types of human ceruminous glands (23). In the wet-type glands, the Golgi apparatus was reportedly well developed, whereas it was generally small in the corresponding cells of the dry type. Furthermore, intracellular granules were abundantly observed in the wet-type gland in close relationship to their well-developed Golgi apparatus, whereas intracellular granules were rare in the dry-type gland.

The ER and Golgi apparatus are the sites of synthesis and maturation of proteins destined for the plasma membrane, for the secretory and endocytic organelles, and for secretion (27, 28). Efficient quality-control systems have evolved to prevent incompletely folded proteins from moving along the secretory pathway. Accumulation of misfolded proteins in the ER would detrimentally affect cellular functions. Therefore, misfolded proteins may be removed from the ER by retrotranslocation to the cytosol compartment, where they are degraded by the ubiquitin-proteasome system. This process is known as endoplasmic reticulum-associated degradation (ERAD) (29-32). It is likely that both the SNP variant R180 and the  $\Delta 27$  mutant are recognized as misfolded proteins in the ER and readily undergo the proteasomal degradation. Indeed, the protein levels of both R180 (Fig. 4B) and  $\Delta 27$  (Fig. 6D) were greatly enhanced by treatment of cells with the



**Figure 8.** Diagnosis of SNP 538G>A by SmartAmp assay and DNA sequencing. *A*) Time course of SmartAmp assay reaction with *ABCC11* allele-specific primers. Results of SmartAmp assay (top panels) and DNA sequence analysis (bottom panels) are shown for 3 diploid genotypes of *ABCC11*. *B*) Comparison of SNP analysis data obtained by SmartAmp method and DNA sequencing.


proteasome inhibitor MG132. This protein processing may influence the activity of ceruminous apocrine glands and determine the type of human earwax. In Fig. 9, we schematically illustrate the effects of the SNP on the cellular localization and function of *ABCC11* in secretory cells of the apocrine gland.

**TABLE 1.** Genotyping of the *ABCC11* gene in axillary osmidrosis patients and comparison with earwax type

Diagnosis	<i>ABCC11</i> genotype (538G>A)		
	G/G	G/A	A/A
Axillary osmidrosis			
Positive	1	11	0
Negative	0	0	2
Earwax type			
Wet	1	11	0
Dry	0	0	2

Diagnosis of axillary osmidrosis and earwax type as well as genotyping of *ABCC11* were performed at Fujita Health University School of Medicine according to the protocol approved by the Ethical Review Board. The SNP 538G>A in the *ABCC11* gene was analyzed by both DNA sequencing and the SmartAmp method.

We have recently demonstrated that the intramolecular disulfide bond formation and *N*-linked glycosylation in the extracellular loop are important for stability of human ABC transporter ABCG2 in the ER (33-36). During *de novo* synthesis in the ER, cysteine disulfide bonds are formed, and oligosaccharides are added to asparagine (*N*-linked glycosylation) or serine residues (*O*-glycosylation) of glycoproteins. In general, *N*-linked glycans are added *en bloc* to proteins as "core oligosaccharides" (Glc<sub>3</sub>Man<sub>9</sub>GlcNAc<sub>2</sub>) (27, 29). As described above, Asn838 and Asn844 are glycosylation target sites in human *ABCC11*. The *N*-linked glycans are thought to be subjected to extensive modification as glycoproteins mature and move through the ER *via* the Golgi apparatus to their final destination, for example, intracellular granules and large vacuoles of secretory cells in the apocrine gland. It is puzzling, however, how amino acid alteration at 180 in TM1 affected the *N*-linked glycosylation occurring in the extracellular loop between TM7 and TM8. To answer this question, we assume that the electrostatic charge at aa 180 in the TM1 could interfere with correct folding of the *de novo* synthesized *ABCC11* protein in the ER, as shown in Fig.



**Figure 9.** Schematic illustration of intracellular sorting of ABCC11 WT and proteasomal degradation of R180 and  $\Delta 27$  variants in secretory cells in ceruminous apocrine gland. *De novo* synthesized ABCC11 WT is N-linked glycosylated at Asn838 and Asn844 in the ER, further processed in the Golgi apparatus, and destined for membrane of intracellular granules and vacuoles. Ceruminous components are thought to be transported by ABCC11 WT and sequestered in intracellular granules and vacuoles. SNP variant R180 and  $\Delta 27$  mutant lacking N-linked glycosylation are recognized as misfolded proteins in the ER and readily undergo ubiquitination and proteasomal degradation.

5C. It is important to note, however, that N-linked glycosylation may affect in part the protein stability, but it is not the principal factor for correctly folding and/or enhancing the stability of the ABCC11 protein in the ER. As exemplified by our recent study, substitutions of one single amino acid due to nonsynonymous polymorphisms greatly affected the protein stability of SNP variants of human ABCG2 (33), whereas deletion of N-linked glycosylation at Asn596 reduced the protein expression level of ABCG2 WT only by half, without any change in its plasma membrane localization (unpublished results). Thus, molecular mechanisms underlying the misfolding and degradation of membrane proteins appear to be rather complex, as they involve interactions with different chaperone proteins.

At present, it remains unclear how misfolded membrane proteins are selected and destroyed during ERAD. Chaperones are considered to solubilize aggregation-prone motifs. In the case of the yeast ABC transporter Ste6p, a 12-transmembrane protein, it has recently been shown that Hsp70/40s act before ubiquitination and facilitate Ste6p association with an E3 ubiquitin ligase (37). Furthermore, polyubiquitination was a prerequisite for retrotranslocation, which required the Cdc48 complex and ATP (37). In this regard, Wang *et al.* (38) and Younger *et al.* (39) recently provided new insights into the complexity of protein networks that govern the fate of the cystic fibrosis transmembrane conductance regulator (CFTR), an apical membrane ABC transporter. The loss of phenylalanine residue at position 508 in the first nucleotide-

binding domain disrupts the folding pathway of CFTR protein in the ER, and subsequently misfolded CFTR is targeted for ERAD (38-42). In the case of human bile salt export pump (BSEP/ABCB11), at least two N-linked glycans are reportedly important for protein stability, intracellular trafficking, and function in the apical membrane (43). In this context, it is increasingly important to identify and to characterize multiple chaperone proteins that control the folding and degradation of ABC transporter proteins, including ABCC11.

### Clinical relevance of genetic polymorphisms of human ABCC11

Genetic polymorphisms of human ABC transporter genes are reportedly related to the risk of disease and patient response to medication (44, 45). Phenotype-based studies have suggested positive associations among the wet-type earwax, axillary osmidrosis (1), colostrum secretion from the mammary gland (2), and the potential susceptibility of breast cancer (4). Our genotyping study has revealed that the ABCC11 WT allele is intimately associated with axillary osmidrosis (Table 1). Since the frequency of the ABCC11 WT allele is low in Japan, axillary osmidrosis is recognized as a disease that is covered by the national health insurance system. Axillary osmidrosis is often perceived, especially by young women, as a distressing and troublesome problem.

Sweat produced by axillary glands is odorless. Secretions from the apocrine glands, however, can be converted to odoriferous compounds by bacteria (*Corynebacteria*), which results in the formation of the unique "human axillary odor" (46). In axillary osmidrosis patients (G/G homozygote or G/A heterozygote), significantly numerous and larger-sized axillary apocrine glands were observed as compared with the subjects carrying the A/A homozygote. Our results (Table 1) suggest that the 538G allele of the ABCC11 gene is associated with axillary osmidrosis and that ABCC11 WT is responsible for the secretion of preodoriferous compounds from the axillary apocrine gland.

In primates, the axillary odors may play a role in olfactory communication, although no documented behavioral or endocrine changes by volatiles produced in the axillae have been reported to occur in humans. Previous studies have shown that androgen steroids were present in the axillary area. Androsterone sulfate (AS) and DHEAS were detected in the extract of axillary hairs, in addition to high levels of cholesterol (47). It was also demonstrated, following injection of radioactive pregnenolone or progesterone, that steroid secretion was concentrated in the axillary area (48). The axillary sweat collected in these studies from the skin surface, however, represents a mixture of materials from apocrine, eccrine, and sebaceous glands, in addition to desquamating epidermal cells. In this respect, Lebows *et al.* (49) conclusively demonstrated that at least two androgen steroids, AS and DHEAS, in addi-

tion to cholesterol, did exist in pure apocrine secretions. It has more recently been reported that DHAES is transported by ABCC11 WT (13-15). Further studies are needed to define more precisely the substrates for ABCC11 in apocrine glands.

## CONCLUSIONS

Based on the previous phenotype analysis, mortality and frequency rates for breast cancer were reported to be associated with the frequency of the allele for wet-type earwax (4), although the association with breast cancer was controversial (50). Our preliminary genotyping study, however, revealed that the allele of 538G (wild type) in the *ABCC11* gene is associated with risk of breast cancer among a total of 416 Japanese premenopausal women as compared with the 538A (SNP type) allele. The odds ratio was found to be 1.86 (unpublished results). The SNP typing method presented in this study would provide a practical tool to examine a latent genetic link between wet-type earwax and the potential risk of breast cancer. FJ

This study was supported by the Japan Science and Technology Agency (JST) research project, "Development of the world's fastest SNP detection system," to T.I.; by Grant-in-Aid for Scientific Research (A) 18201041 to T.I.; in part by a JST Solution Oriented Research for Science and Technology (SORST) grant to N.N.; by Japanese Society for the Promotion of Science (JSPS) Grant-in-Aid for Exploratory Research 19659136 to T.I.; by Grant-in-Aid for Young Scientists (B) 19791361 to H.N.; by Grant-in-Aid for Scientific Research on Priority Areas 18059027 to K.Y.; and by a Ministry of Education, Culture, Sports, Science and Technology (MEXT) research grant for RIKEN Omics Science Center to Y.H. Y.T. is a JSPS fellow.

## REFERENCES

1. Yoo, W. M., Pac, N. S., Lee, S. J., Roh, T. S., Chung, S., and Tark, K. C. (2006) Endoscopy-assisted ultrasonic surgical aspiration of axillary osmidrosis: a retrospective review of 896 consecutive patients from 1998 to 2004. *J. Plast. Reconstr. Aesthet. Surg.* **59**, 978-982
2. Miura, K., Yoshiura, K., Miura, S., Shimada, T., Yamasaki, K., Yoshida, A., Nakayama, D., Shibata, Y., Niikawa, N., and Masuzaki, H. (2007) A strong association between human earwax-type and apocrine colostrum secretion from the mammary gland. *Hum. Genet.* **121**, 631-633
3. Petrakis, N. L. (1983) Cerumen phenotype and epithelial dysplasia in nipple aspirates of breast fluid. *Am. J. Phys. Anthropol.* **62**, 115-118
4. Petrakis, N. L. (1971) Cerumen genetics and human breast cancer. *Science* **173**, 347-349
5. Gesase, A. P., and Satoh, Y. (2003) Apocrine secretory mechanism: recent findings and unresolved problems. *Histol. Histopathol.* **18**, 597-608
6. Yoshiura, K., Kinoshita, A., Ishida, T., Ninokata, A., Ishikawa, T., Kaname, T., Bannai, M., Tokunaga, K., Sonoda, S., Komaki, R., Ihara, M., Saenko, V., Alipov, G., Sekine, I. O., Komatsu, K., Takahashi, H., Nakashima, M., Sosonkina, N., Mapendano, C., Ghadami, M., Nomura, M., Liang, D.-S., Miwa, N., Dae-Kwang, K., Garidkhuu, A., Natsume, N., Ohta, T., Tomita, H., Kaneko, A., Kikuchi, M., Russomando, G., Hirayama, K., Ishibashi, M., Takahashi, A., Saitou, N., Murray, J. C., Saito, S., Nakamura, Y., and Nikawa, N. (2006) A SNP in the *ABCC11* gene is the determinant of human earwax type. *Nat. Genet.* **38**, 324-330
7. Yabuuchi, H., Shimizu, H., Takayanagi, S., and Ishikawa, T. (2001) Multiple splicing variants of two new human ATP-binding cassette transporters, *ABCC11* and *ABCC12*. *Biochem. Biophys. Res. Commun.* **288**, 933-939
8. Tammur, J., Prades, C., Arnould, I., Rzhetsky, A., Hutchinson, A., Adachi, M., Schuetz, J. D., Swoboda, K. J., Ptacek, L. J., Rosier, M., Dean, M., and Allikmets, R. (2001) Two new genes from the human ATP-binding cassette transporter superfamily, *ABCC11* and *ABCC12*, tandemly duplicated on chromosome 16q12. *Gene* **273**, 89-96
9. Bera, T. K., Lee, S., Salvatore, G., Lee, B., and Pastan, I. (2001) MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. *Mol. Med.* **7**, 509-516
10. Ono, N., Van der Heijden, I., Scheffer, G. L., Van de Wetering, K., Van Deemter, E., De Haas, M., Boerke, A., Gadella, B. M., De Rooij, D. G., Neeffjes, J. J., Groothuis, T. A. M., Oomen, L., Brocks, L., Ishikawa, T., and Borst, P. (2007) Multidrug resistance-associated protein 9 (*ABCC12*) is present in mouse and boar sperm. *Biochem. J.* **406**, 31-40
11. Shimizu, H., Taniguchi, H., Hippo, Y., Hayashizaki, Y., Aburatani, H., and Ishikawa, T. (2003) Characterization of the mouse *Abcc12* gene and its transcript encoding an ATP-binding cassette transporter, an orthologue of human *ABCC12*. *Gene* **310**, 17-28
12. Toyoda, Y., Hagiya, Y., Adachi, T., Hoshijima, K., Kuo, M. T., and Ishikawa, T. (2008) MRP class of human ATP binding cassette (ABC) transporters: historical background and new research directions. *Xenobiotica* **38**, 833-862
13. Kruh, G. D., Guo, Y., Hopper-Borge, E., Belinsky, M. G., and Chen, Z. S. (2007) *ABCC10*, *ABCC11*, and *ABCC12*. *Pflügers Arch.* **453**, 675-684
14. Bortfeld, M., Rius, M., König, J., Herold-Mende, C., Nies, A. T., and Keppler, D. (2006) Human multidrug resistance protein 8 (*MRP8/ABCC11*), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. *Neuroscience* **137**, 1247-1257
15. Chen, Z. S., Guo, Y., Belinsky, M. G., Kotova, E., and Kruh, G. D. (2005) Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (*ABCC11*). *Mol. Pharmacol.* **67**, 545-557
16. Guo, Y., Kotova, E., Chen, Z. S., Lee, K., Hopper-Borge, E., Belinsky, M. G., and Kruh, G. D. (2003) *MRP8*, ATP-binding cassette C11 (*ABCC11*), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine. *J. Biol. Chem.* **278**, 29509-29514
17. Yamaguchi-Kabata, Y., Nakazono, K., Takahashi, A., Saito, S., Hosono, N., Kubo, M., Nakamura, Y., and Kamatani, N. (2008) Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. *Am. J. Hum. Genet.* **83**, 445-456
18. Kyte, J., and Doolittle, R. F. (1982) A simple method for displaying the hydrophobic character of a protein. *J. Mol. Biol.* **157**, 105-132
19. Nakashima, M., Meirmanov, S., Matsufuji, R., Hayashida, M., Fukuda, E., Naito, S., Matsui, M., Shichijo, K., Kondo, H., Ito, M., Yamashita, S., and Sekine, I. (2002) Altered expression of beta-catenin during radiation-induced colonic carcinogenesis. *Pathol. Res. Pract.* **198**, 717-724
20. Tamura, A., Wakabayashi, K., Onishi, Y., Takeda, M., Ikegami, Y., Sawada, S., Tsuji, M., Matsuda, Y., and Ishikawa, T. (2007) Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter *ABCG2*. *Cancer Sci.* **98**, 231-239
21. Wakabayashi, K., Nakagawa, H., Adachi, T., Kii, I., Kobatake, E., Kudo, A., and Ishikawa, T. (2006) Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter *ABCG2*: a new approach using the flp recombinase system. *J. Exp. Ther. Oncol.* **5**, 205-222
22. Tamura, A., Wakabayashi, K., Onishi, Y., Nakagawa, H., Tsuji, M., Matsuda, Y., and Ishikawa, T. (2006) Genetic polymorphisms of human ABC transporter *ABCG2*: development of the standard method for functional validation of SNPs by using the Flp recombinase system. *J. Exp. Ther. Oncol.* **6**, 1-11



23. Shugyo, Y., Sudo, N., Kanai, K., Yamashita, T., Kumazawa, T., and Kanamura, S. (1988) Morphological differences between secretory cells of wet and dry types of human ceruminous glands. *Am. J. Anat.* **181**, 377–384
24. Mitani, Y., Lezhava, A., Kawai, Y., Kikuchi, T., Oguchi-Katayama, A., Kogo, Y., Itoh, M., Miyagi, T., Takakura, H., Hoshi, K., Kato, C., Arakawa, T., Shibata, K., Fukui, K., Masui, R., Kuramitsu, S., Kiyotani, K., Chalk, A., Tsunekawa, K., Murakami, M., Kamataki, T., Oka, T., Shimada, H., Cizdziel, P. E., and Hayashizaki, Y. (2007) Rapid SNP diagnostics using asymmetric isothermal amplification and a new mismatch-suppression technology. *Nat. Methods* **4**, 257–262
25. Kawai, Y., Kikuchi, T., Mitani, Y., Kogo, Y., Itoh, M., Usui, K., Kanamori, H., Kaiho, A., Takakura, H., Hoshi, K., Cizdziel, P. E., and Hayashizaki, Y. (2008) Sensitive detection of EGFR mutations using a competitive probe to suppress background in the SMart Amplification Process. *Biologicals* **36**, 234–238
26. Watanabe, J., Mitani, Y., Kawai, Y., Kikuchi, T., Kogo, Y., Oguchi-Katayama, A., Kanamori, H., Usui, K., Itoh, M., Cizdziel, P. E., Lezhava, A., Tatsumi, K., Ichikawa, Y., Togo, S., Shimada, H., and Hayashizaki, Y. (2007) Use of a competitive probe in assay design for genotyping of the UGT1A1\*28 microsatellite polymorphism by the smart amplification process. *BioTechniques* **43**, 479–484
27. Helenius, A., and Aebi, M. (2004) Roles of N-linked glycans in the endoplasmic reticulum. *Annu. Rev. Biochem.* **73**, 1019–1049
28. Ellgaard, L., Molinari, M., and Helenius, A. (1999) Setting the standards: quality control in the secretory pathway. *Science* **286**, 1882–1888
29. Klitzgen, B., and Braakman, I. (2004) Protein folding and quality control in the endoplasmic reticulum. *Curr. Opin. Cell Biol.* **16**, 343–349
30. Hampton, R. Y. (2002) ER-associated degradation in protein quality control and cellular regulation. *Curr. Opin. Cell Biol.* **14**, 476–482
31. Ellgaard, L., and Helenius, A. (2001) ER quality control: towards an understanding at the molecular level. *Curr. Opin. Cell Biol.* **13**, 431–437
32. Mori, K. (2000) Tripartite management of unfolded proteins in the endoplasmic reticulum. *Cell* **101**, 451–454
33. Nakagawa, H., Tamura, A., Wakabayashi, K., Hoshijima, K., Komada, M., Yoshida, T., Kometani, S., Matsubara, T., Mikuriya, K., and Ishikawa, T. (2008) Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2. *Biochem. J.* **411**, 623–631
34. Wakabayashi, K., Nakagawa, H., Tamura, A., Koshiha, S., Hoshijima, K., Komada, M., and Ishikawa, T. (2007) Intramolecular disulfide bond is a critical check point determining degradative fates of ATP-binding cassette (ABC) transporter ABCG2 protein. *J. Biol. Chem.* **282**, 27841–27846
35. Furukawa, T., Wakabayashi, K., Tamura, A., Nakagawa, H., Morishima, Y., Osawa, Y., and Ishikawa, T. (2009) Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations. *Pharm. Res.* **26**, 469–479
36. Wakabayashi-Nakao, K., Tamura, A., Furukawa, T., Nakagawa, H., and Ishikawa, T. (2009) Quality control of human ABCG2 protein in the endoplasmic reticulum: Ubiquitination and proteasomal degradation. *Adv. Drug Deliv. Rev.* **61**, 66–72
37. Nakatsukasa, K., Huyer, G., Michaelis, S., and Brodsky, J. L. (2008) Dissecting the ER-associated degradation of a misfolded polytopic membrane protein. *Cell* **132**, 101–112
38. Wang, X., Venable, J., LaPointe, P., Hutt, D. M., Koulov, A. V., Coppinger, J., Gurkan, C., Kellner, W., Matteson, J., Plutner, H., Riordan, J. R., Kelly, J. W., Yates, J. R., and Balch, W. E. (2006) Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. *Cell* **127**, 803–815
39. Younger, J. M., Chen, L., Ren, H. Y., Rosser, M. F., Turnbull, E. L., Fan, C. Y., Patterson, C., and Cyr, D. M. (2006) Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator. *Cell* **126**, 571–582
40. Skach, W. R. (2006) CFTR: new members join the fold. *Cell* **127**, 673–675
41. Riordan, J. R. (2005) Assembly of functional CFTR chloride channels. *Annu. Rev. Physiol.* **67**, 701–718
42. Qu, B. H., Strickland, E. H., and Thomas, P. J. (1997) Localization and suppression of a kinetic defect in cystic fibrosis transmembrane conductance regulator folding. *J. Biol. Chem.* **272**, 15739–15744
43. Mochizuki, K., Kagawa, T., Numari, A., Harris, M. J., Itoh, J., Watanabe, N., Mine, T., and Arias, I. M. (2007) Two N-linked glycans are required to maintain the transport activity of the bile salt export pump (ABCB11) in MDCK II cells. *Am. J. Physiol. Gastrointest. Liver Physiol.* **292**, G818–G828
44. Ishikawa, T. (2003) Multidrug resistance in cancer: Genetics of ABC transporters. In *Nature Encyclopedia of the Human Genome*, Vol. 4 (Cooper, D. N., ed) pp. 154–160, Nature Publishing Group, London
45. Borst, P., and Elferink, R. O. (2002) Mammalian ABC transporters in health and disease. *Annu. Rev. Biochem.* **71**, 537–592
46. Shchadch, N. H., and Kligman, A. M. (1963) The effect of topical antibacterial agents on the bacterial flora of the axilla. *J. Invest. Dermatol.* **40**, 61–71
47. Julesz, M. (1968) New advances in the field of androgenic steroidogenesis of the human skin. *Acta Med. Acad. Sci. Hung.* **25**, 273–285
48. Brooksbank, B. W. (1970) Labelling of steroids in axillary sweat after administration of 3H-delta-5-pregnenolone and 14C-progesterone to a healthy man. *Experientia* **26**, 1012–1014
49. Labows, J. N., Preti, G., Hoelzle, E., Leyden, J., and Kligman, A. (1979) Steroid analysis of human apocrine secretion. *Steroids* **34**, 249–258
50. Ing, R., Petrakis, L., and Ho, H. C. (1973) Evidence against association between wet cerumen and breast cancer. *Lancet* **1**, 41

Received for publication February 24, 2009.

Accepted for publication April 9, 2009.

Research article

Open Access

## A strong association of axillary osmidrosis with the wet earwax type determined by genotyping of the *ABCC11* gene

Motoi Nakano<sup>1</sup>, Nobutomo Miwa<sup>2,4</sup>, Akiyoshi Hirano<sup>1</sup>, Koh-ichiro Yoshiura<sup>\*2,4</sup> and Norio Niikawa<sup>3,4</sup>

Address: <sup>1</sup>Department of Reconstruction and Plastic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, <sup>2</sup>Department of Human Genetics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, <sup>3</sup>Research Institute of Personalized Health Sciences, Health Sciences University of Hokkaido, Hokkaido, Japan and <sup>4</sup>Solution Oriented Research of Science and Technology (SORST), Japan Science and Technology Agency (JST), Tokyo, Japan

Email: Motoi Nakano - [motoi@hospital.sasebo.nagasaki.jp](mailto:motoi@hospital.sasebo.nagasaki.jp); Nobutomo Miwa - [ana09948@nifty.ne.jp](mailto:ana09948@nifty.ne.jp); Akiyoshi Hirano - [akiyoshi@nagasaki-u.ac.jp](mailto:akiyoshi@nagasaki-u.ac.jp); Koh-ichiro Yoshiura\* - [kyoshi@nagasaki-u.ac.jp](mailto:kyoshi@nagasaki-u.ac.jp); Norio Niikawa - [niikawa@hoku-iryu-u.ac.jp](mailto:niikawa@hoku-iryu-u.ac.jp)

\* Corresponding author

Published: 4 August 2009

Received: 3 August 2008

BMC Genetics 2009, 10:42 doi:10.1186/1471-2156-10-42

Accepted: 4 August 2009

This article is available from: <http://www.biomedcentral.com/1471-2156/10/42>

© 2009 Nakano et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Two types of cerumen occur in humans: the wet type with brownish, sticky earwax, and the dry type with a lack of or reduced ceruminous secretion. The wet type is common in populations of European and African origin, while the dry type is frequently seen in Eastern Asian populations. An association between axillary odor and the wet-type earwax was first identified approximately 70 years ago. The data were based on a phenotypical analysis of the two phenotypes among the Japanese by a researcher or by self-declaration of the subjects examined, and were not obtained using definite diagnostic methods. Recently, we identified a single-nucleotide polymorphism (SNP; rs17822931) of the *ABCC11* gene as the determinant of the earwax types. In the present study, to determine whether the SNP can serve as a diagnostic marker for axillary osmidrosis (AO), we examined genotypes at rs17822931 in 79 Japanese AO individuals. AO was defined here as a clinical condition of individuals with a deep anxiety regarding axillary odor and had undergone the removal of bilateral axillary apocrine glands.

**Results:** A comparison of the frequencies of genotypes at rs17822931 in the 79 AO individuals and in 161 Japanese from the general population showed that AO was strongly associated with the wet earwax genotype. A total of 78 (98.7%) of 79 AO patients had either the GG or GA genotype, while these genotypes were observed in 35.4% (57/161) of the subjects from the general population ( $p < 1.1 \times 10^{-24}$ , by Fisher's exact test).

**Conclusion:** The strong association between the wet-earwax associated *ABCC11*-genotypes (GG and GA) and AO identified in this study indicates that the genotypes are good markers for the diagnosis of AO. In addition, these results suggest that having the allele G is a prerequisite for the axillary odor expression. In other words, the *ABCC11* protein may play a role in the excretory function of the axillary apocrine gland. Together, these results suggest that when an AO individual visiting a hospital is diagnosed with dry-type earwax by *ABCC11*-genotyping, surgical removal of their axillary glands may not be indicated.

## Background

Apocrine and/or eccrine glands in the human body cause odor, especially from the axillary and pubic apocrine glands. As in other mammals, the odor may have a pheromone-like effect on the opposite sex. Although the odor does not affect health, axillary osmidrosis (AO) is a condition in which an individual feels uncomfortable with their axillary odor, regardless of its strength, and may visit a hospital. Surgery to remove the axillary gland may be performed on demand. AO is likely an oligogenic trait with rs17822931 accounting for most of the phenotypic variation and other unidentified functional variants accounting for the remainder. However, no definite diagnostic criteria or objective measuring methods have been developed to characterize the odor, and whether an individual suffers from AO depends mainly on their assessment and/or on examiner's judgment. Human body odor may result from the breakdown of precursors into a pungent odorant by skin bacteria [1], but it is unclear if AO is this type of odor.

The consistency of human earwax is a dimorphic genetic trait and two distinct types are known: the wet type characterized as sticky, brownish earwax, and the dry type characterized as scurf or scales of the external ear canal. The wet type is completely dominant to the dry type, and is very common in populations of European and African origin (~95% and ~100%, respectively) [2-7]. In contrast, the dry type is frequently seen in Eastern Asian populations, with the prevalence of the wet earwax being ~15% in Japan, ~5% in Korea and ~10% among the Han Chinese [2,7]. We have recently identified an earwax determining SNP, c.538G>A (rs17822931), in the *ABCC11*

gene [6], and confirmed the gene as an earwax-type determinant. We calculated the allele frequencies in various ethnic populations [6], which can now be retrieved from existing databases. From the HapMap data, the G-allele (defining the wet type) frequency is estimated to be 1.000 in the Yoruba population (Africa), 0.875 in CEPH families (Europe), and 0.111 in Tokyo habitants (Japan), and the frequencies estimated from ALFRED (the allele frequency database) show overall accordance with those from the HapMap data.

A relationship between axillary odor and the wet-type earwax was first noticed among the Japanese population concurrent with the first discovery of the earwax type as a Mendelian trait. Japanese clinicians assert an association between axillary odor and earwax type; however, since no definite diagnostic criteria or measuring methods were available for the two traits, the data is based on observations of the two respective traits.

Here we report the result of a genotyping study examining rs17822931 of the *ABCC11* gene in Japanese individuals with AO, and discuss the *ABCC11* genotype as a diagnostic tool for AO.

## Results

We analyzed a total of 79 AO individuals from either Nagasaki or Okinawa prefectures. Of the 79 AO patients, 5 were GG homozygotes, 73 were GA heterozygotes, and 1 was an AA homozygote. Therefore, 98.7% (78/79) of the AO individuals had the GG or GA genotype (Table 1). In contrast, the GG and GA genotypes were observed in 35.4% (57/161) of the overall population in the prefec-

**Table 1: Association of AO with the wet earwax type**

Subject studied	Genotype at the rs17822931 locus (earwax phenotype)					
	GG	GA	(wet type)	AA	(dry type)	total
Individuals with AO (Kyushu)	5	73	(78) <sup>a</sup>	1	(1) <sup>a</sup>	79
General habitants in Kyushu	6	51	(57) <sup>a</sup>	104	(104) <sup>a</sup>	161
total			(135) <sup>a</sup>		(105) <sup>a</sup>	240
Individuals with AO (Okinawa)	3	34	(37) <sup>b</sup>	1	(1) <sup>b</sup>	38
General habitants in Okinawa	2	15	(17) <sup>b</sup>	17	(17) <sup>b</sup>	34
total			(54) <sup>b</sup>		(18) <sup>b</sup>	72
Individuals with AO (Nagasaki)	2	39	(41) <sup>c</sup>	0	(0) <sup>c</sup>	41
General habitants in Nagasaki	4	36	(40) <sup>c</sup>	87	(87) <sup>c</sup>	127
total			(81) <sup>c</sup>		(87) <sup>c</sup>	168

<sup>a</sup> $p < 1.1 \times 10^{-24}$ , <sup>b</sup> $p < 3.0 \times 10^{-6}$ , <sup>c</sup> $p < 8.4 \times 10^{-17}$ ; all comparisons were performed under a dominant model. All statistical analyses were done by Fisher's exact test. Hardy-Weinberg equilibrium was supported under the observed allele frequency in control samples by Exact Hardy-Weinberg test ( $p$ -value > 0.1) [18]. These comparisons were performed using plink software [19] <http://pngu.mgh.harvard.edu/purcell/plink/>.

tures. In Nagasaki, GG, GA and AA genotypes are observed in 2, 39 and none of the 41 AO individuals, and in 4, 36 and 87 of the general population samples, respectively. Likewise in Okinawa prefecture, GG, GA and AA genotypes comprised 3, 34, and 1 of the AO patients, and 2, 15, and 17 of the general Okinawans population sample. Fisher's exact test showed a strong association between the wet type genotype and AO ( $p < 8.4 \times 10^{-17}$  for the Nagasaki habitants, and  $p < 3.0 \times 10^{-6}$  for the Okinawans) (Table 1). Although G allele frequency is considerably higher among Okinawans than habitants in other Kyushu areas [6], no significant difference was detected between general Nagasaki and Okinawa populations ( $p > 0.06$ ). This may be due to the relatively small number of samples from Okinawa in this study. Fisher's exact test of the combined data showed a strong association of the wet type genotype and AO ( $p < 1.1 \times 10^{-24}$ ).

### Discussion

We have shown that AO in the Japanese population is strongly associated with the wet earwax genotypes, with the results supporting the 70-year-old data of a strong, positive association between the two traits. If all AO in the Japanese is a Mendelian trait and is primarily determined by allele G at the c.538G/A polymorphic site in the *ABCC11* gene, an all-or-none result would have been expected. In other words, under this condition, AA homozygotes should not have been included in the AO group, and all individuals with GG or GA genotype should have AO. However, a single individual with the AA genotype was present in our series of AO samples, and, thus, not all the samples showed deterministic association (Table 1). Since no objective way to quantify or qualify axillary odor is available and the diagnosis of any given AO individual is made on the basis of their history and complaints, we focused in this study only on AO individuals who visited plastic surgery clinics and did not assess the odor quantity of GG and GA individuals in the general population. Some individuals without AO may exist, and their axillary odor may be controlled by other genes and/or factors that modify the *ABCC11* function. Primary (cause unknown and possibly genetic) and secondary (multiple causes including anxiety, menopause, hyperthyroidism, stroke, drugs, amongst other causes) hyperhidrosis may be an explicable factor for AO in individuals with the AA genotype. It is plausible that the *ABCC11* gene primarily determines the quality of AO, while modifiers play a role in its quantity, such as pre-determination regarding the number of the apocrine glands in the axilla.

The *ABCC11* gene, which encodes MRP8, is expressed in various types of tissues [8,9] and is a member of the ATP-binding cassette transporter gene family [10]. Most ABC transporter proteins are localized to the plasma membrane and are ATP-dependent transporters of a broad

range of compounds [11], such as cyclic nucleotides, lipophilic anions (glutathione-conjugated LTC<sub>4</sub>), sulfated steroids (DHEAS and E<sub>1</sub>3S), glucuronides (E<sub>2</sub>17βG), bile constituents (glycocholate and taurocholate), and monoglutamates (methotrexate) [12]. MRP8 is localized to the apical membrane of MDCK cells when expressed artificially [13]. Since most MRP proteins transport substrates from the inside to the outside of the cell, certain compound(s) that may cause axillary odor are secreted through MRP8 in the axillary apocrine gland. The axillary gland of individuals with the wet earwax type may secrete the materials more highly than that of the dry type individuals, as seen in a previous in vitro experiment [6].

The nature of axillary odor and whether the axillary odorants come directly from secreted materials of the axillary gland are unknown. Some carboxylic acids were reported to be possible components of such odorants. Zeng et al. [14] demonstrated that (*E*)-3-methylhex-2-enoic acid (3M2H) is a key odorant component, and its hydrated analogue (*RS*)-3-hydroxy-3-methylhexanoic acid (HMHA) was the most abundant pungent odorant in the axilla [15]. Sweat itself does not smell, but skin bacteria (*Corynebacteria*) transform non-odoriferous precursors in sweat into a pungent odorant [1]. In addition, a specific Zn-dependent *N*-acyl-glutamine aminoacylase (N-AGA) in the bacteria has been reported to catalyze a reaction that produces 3M2H and HMHA from *N*-acyl-glutamine conjugates secreted into sweat in the axilla [15]. Natsch et al. [16] claimed that since there are other odoriferous materials, the proportion of these components causes odor variance among individuals. However, since axillary odor can be detected immediately after sweating (especially a large amount of rapid nervous sweating), there is insufficient time for bacterial growth. In addition, since the odor does not completely disappear by washing with water, but disappears with the use of soap, axillary odorants may contain certain lipophilic components, as does earwax. Therefore, it remains unclear whether these precursors in sweat are substrates of MRP8 and their secretion might be reduced or lacking in individuals with dry type earwax.

Recently, we examined the biochemical characteristics of the G allele (wild type allele) and A allele (mutant allele) [17]. Our results showed that the wild type *ABCC11* protein is glycosylated and localized to the ceruminous gland membrane, but mutant *ABCC11* from the A allele is not glycosylated and is degraded rapidly by the proteasome system. Degradation by the proteasome is not a complete process and some of the protein is localized on the cell surface membrane; therefore, mutant *ABCC11* may retain some excretion function [17]. In this context, body odorant derived from *ABCC11* function may represent a quantitative trait that depends on the protein levels on the cell

surface. Previously, we reported on the excretion properties of wild type and mutant ABCC11 using cGMP as a substrate. Since cGMP is not an authentic substrate for odor, further work is needed to identify the odorant in AO or from the ABCC11 substrate not only for biochemical characterization, but also as an objective tool to measure the axillary odor.

### Conclusion

In the present study, we demonstrated a strong association between the wet earwax genotype and AO. Our results suggest that genotyping at the rs17822931 locus may be a useful tool for supplementing the diagnosis of patients that present at clinic with OA. A result of this study suggests that the presence of allele G at the rs17822931 locus is a prerequisite for AO. Since almost all of the patients complaining of AO in this study did not have the AA genotype (78/79), we suggest that further study may prove rs17822931 to provide useful additional information in diagnosing AO patients. Two key issues remain to be addressed. The first is that, although the estimated sensitivity of the genotype diagnostic test from this study is high (approximately 99%) for patients who present with AO, the specificity of the test in this context is low, with 35% of controls also carrying the G risk allele. Second, it is vital that further research identify more objective clinical definitions of AO, since the sensitivity and specificity data presented in this study are conditional upon the subjective diagnosis of AO.

### Methods

#### Subjects studied

The examinees included 79 Japanese individuals with AO, who were examined at plastic surgery clinics. Of the 79 AO samples, 41 were from Nagasaki prefecture and the remaining 38 were from Okinawa prefecture. Both prefectures are located in the Kyushu area, the most western district of Japan. Wet earwax frequency is different among prefectures of Japan [2], so we divided the samples into two groups based on the prefectures. One hundred twenty seven samples in Nagasaki and 34 samples in Okinawa were used as general population controls for chi-square test. These samples were previously collected for calculating the allele frequency of rs17822931 in ABCC11. All of the samples from AO cases and controls were collected with written informed consent, and protocols for the present study were approved by the Committee for the Ethical Issues on Human Genome and Gene Analysis at Nagasaki University.

In this study, AO individuals were defined as those who were anxious about axillary odor and had received a surgical operation in the clinics to remove their axillary apocrine glands. In general, some Japanese are very sensitive and nervous of body odor and often visit the clinics, prob-

ably because the majority of the population have faint odor. From this background, plastic surgeons are familiar with AO and the collection of AO patients is easy. However, no objective diagnostic methods are available for axillary odor. Therefore, diagnosis of AO was made through self-declaration by the individual and through the clinician's judgment at interview prior to the operation. Earwax type was not considered for the AO diagnosis. Although AO due to primary and secondary hyperhidrosis was excluded as much as possible, individuals with such conditions may have been included in our samples. If we collected samples from individuals with faint axillary odor (or without odor), well-trained plastic surgeons who collected the "AO" patient judged the axillary odor. In this situation, our association could be defined as a double blind study, but it is difficult to smell the axilla in the general population. Therefore, we focused our interest on the measurement the sensitivity of the earwax genotype to judge AO. When objective diagnostic methods are available for axillary odor, a complete double blind study will be feasible.

#### Genotyping at the SNP site (rs17822931) and association study

Genomic DNA was extracted from all examinees, and was subjected to PCR-based genotyping at the SNP site, rs17822931 (c.538G>A), in the ABCC11 gene. For the TaqMan genotyping, VIC-labeled TaqMan MGB wet-probe (5'-CAGTGTACTCGGGCCAG-3') and FAM-labeled TaqMan MGB dry-probe (5'-CAGTGTACTCAGGCCAG-3') were used as hydrolyzing probes, while EW-ampF (5'-CTTCTGGGCATCTGCTTCTG-3') and EW-ampR (5'-CAAACCTCACCAGTCTGCCA-3') were used as amplification primers. Reactions were carried out using TaqMan Universal PCR Master Mix (AppliedBiosystems). Homozygotes for allele A were categorized to have the dry earwax type and others the wet type [6]. The number of AO individuals within each respective genotype was statistically compared with that in the general population by Fisher's exact test, and Hardy-Weinberg equilibrium was tested under the observed allele frequency [18,19].

#### Authors' contributions

MN collected samples from the Nagasaki area and extracted DNA. NM extracted DNA from tissue samples of AO individuals and performed genotyping. AH participated in the design of the study, collected samples from the Okinawa area and analyzed the clinical data of AO patients. KY performed statistical analysis. KY and NN participated in the design of the study and supervised the above researchers/clinicians and prepared the manuscript. All authors read and approved the final manuscript.

#### Acknowledgements

N.N. was supported in part by Grants-in-Aid for Scientific Research (on Priority Areas – Applied Genomics, No. 17019055; and Category B, No.